Rinza 10 tablets — Made in India — Free Delivery

Pharmacological properties

Rinza® is a combined preparation with analgesic, antipyretic and anti-inflammatory action, which is due to the components that make up the preparation.

Paracetamol has analgesic and antipyretic effects. The analgesic effect is due to the inhibitory effect on the synthesis of prostaglandins. The antipyretic effect is mediated by the effect on the hypothalamic center of thermoregulation.

Chlorpheniramine maleate is a blocker of H1-histamine receptors. Inhibits the biological effects of histamine: helps to reduce the severity of cold symptoms, manifestations of allergic rhinitis and sinusitis, improves nasal breathing, reduces runny nose, helps to eliminate sneezing and lacrimation.

Caffeine is a stimulant of the central nervous system, it stimulates the respiratory and vasomotor centers, stimulates cardiac activity and increases the strength of myocardial contractions, reduces fatigue and drowsiness.

Phenylephrine hydrochloride stimulates α-adrenergic receptors of vascular smooth muscle. Thus, it has a vasoconstrictor effect, helps to reduce edema and hyperemia of the mucous membrane of the upper respiratory tract and nasal sinuses.

Indications

Symptomatic treatment of colds, flu and acute viral diseases of the respiratory tract (fever, pain, runny nose).

Application

For adults and children over the age of 15, Rinza® is prescribed 1 tablet 3-4 times a day, 1-2 hours after a meal. drink plenty of fluids. the maximum daily dose is 4 tablets. the duration of the preparation intake is no more than 5 days.

Contraindications

Hypersensitivity to any of the components of the preparation; severe atherosclerosis of the coronary vessels; severe cardiovascular diseases, including conduction disturbances, severe coronary artery disease; decompensated heart failure; severe form of ag; tendency to vasospasm; thrombosis; thrombophlebitis; severe renal and liver dysfunction; insufficiency of glucose-6-phosphate dehydrogenase; congenital hyperbilirubinemia; club-johnson syndrome; acute pancreatitis; diabetes; diseases of the thyroid gland; pyloroduodenal obstruction; ba; hoble; emphysema; Chronical bronchitis; Stevens-Johnson syndrome; pheochromocytoma; hyperthyroidism; blood diseases; severe leukopenia; anemia; obstruction of the bladder neck; hypertrophy of the prostate gland with difficulty urinating, hyperplasia of the prostate gland; increased intraocular pressure; angle-closure glaucoma; increased excitability, sleep disturbance; epilepsy; alcoholism; elderly age; hypersensitivity to other xanthine derivatives (theophylline, theobromine); do not use in conjunction with antidepressants; do not use together with β-adrenergic receptor blockers; do not use together with MAO inhibitors and within 2 weeks after discontinuation of MAO inhibitors.

Side effects

In most cases, the preparation is well tolerated. side effects caused by the constituents of the preparation were rarely noted, as a rule, as a result of prolonged use of the preparation in high doses.

From the digestive tract: heartburn, epigastric discomfort, hypersalivation, decreased appetite, nausea, vomiting, constipation, diarrhea or flatulence. With prolonged use of significant doses of the preparation - pain in the epigastric region.

From the hepatobiliary system: impaired liver function, increased activity of hepatic enzymes, usually without the development of jaundice, hepatonecrosis (when using high doses), hepatotoxic effect.

Disorders of nutrition and metabolism: hypoglycemia, up to hypoglycemic coma.

Cardiac disorders: tachycardia, reflex bradycardia, arrhythmia, shortness of breath, heart pain.

Vascular disorders: increased blood pressure (especially in patients with hypertension).

From the nervous system: headache, fear, general weakness, dizziness; psychomotor agitation and disorientation, insomnia, anxiety, anxiety, irritability or nervousness, tremors, confusion, depression, tingling and heaviness in the limbs, dyskinesia, tinnitus, epileptic seizures, convulsions, coma.

Mental disorders: hallucinations, behavior changes.

From the kidneys and urinary tract: nephrotoxicity (including renal colic, interstitial nephritis, papillary necrosis), urinary disorders, dysuria, urinary retention and stranguria (difficulty urinating).

From the blood and lymphatic system: bruising or bleeding, anemia, hemolytic anemia, methemoglobinemia, thrombocytopenia, aplastic anemia, pancytopenia, sulfhemoglobinemia, neutropenia, agranulocytosis, leukopenia.

From the respiratory system, chest and mediastinal organs: bronchospasm in patients sensitive to acetylsalicylic acid and other NSAIDs.

From the side of the organ of vision: visual impairment and dry eyes, mydriasis, impaired accommodation, increased intraocular pressure.

From the immune system: skin rash, generalized rash, itching, urticaria, hyperemia; bronchial obstruction, exudative erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis; hypersensitivity reactions, including anaphylaxis, anaphylactic shock, angioedema. Sometimes, allergic-type reactions, including attacks of asthma, are noted in patients with intolerance to acetylsalicylic acid.

General disorders and reactions at the injection site: sleep disturbance, dry mouth or throat; drowsiness, general weakness, increased sweating.

Special instructions

Do not exceed the indicated dose. Simultaneous use with other medicinal products containing paracetamol or other active ingredients that are part of the Rinza® preparation should be avoided. this preparation is not recommended to be used simultaneously with sedatives, hypnotics.

The preparation should be prescribed by a doctor only after assessing the risk / benefit ratio in the following cases: hypertension; prostate adenoma; heart rhythm disorder; disorders of urination. Prescribe cautiously in case of productive cough, in patients with a congenital prolonged Q – T interval, or in cases of prolonged use of preparations that can prolong the Q – T interval.

If, on the recommendation of a doctor, the preparation is used for a long period, it is necessary to monitor the functional state of the liver and the picture of peripheral blood.

Before using the preparation, you should consult your doctor when using warfarin or similar preparations that have an anticoagulant effect. The preparation may affect the results of laboratory tests on the content of glucose and uric acid in the blood.

When using the preparation, avoid excessive consumption of coffee, strong tea, other tonic drinks, alcohol, as well as the use of preparations containing caffeine. This can cause sleep problems, tremors, tension, irritability, chest discomfort due to palpitations, dizziness, and arrhythmias.

During treatment with Rinza®, you should refrain from drinking alcohol.

Taking Rinza® can cause a positive analytical result of doping control.

If a high temperature persists for 3 days or more, or occurs again, and the pain does not stop for more than 5 days, you should consult a doctor.

Use during pregnancy and lactation. It is not recommended to use the preparation during pregnancy and lactation.

Children. Not recommended for children under 15 years of age.

The ability to influence the reaction rate when driving or working with other mechanisms. During the use of the preparation, you should not drive vehicles and work with potentially dangerous mechanisms.

Interactions

Avoid simultaneous use with other medicinal products containing paracetamol or other active ingredients that make up Rinza®.

Rinza® potentiates the effect of MAO inhibitors, β-adrenergic receptor blockers, sedatives and ethanol. In addition, MAO inhibitors and furazolidone, when used together with Rinza®, can cause agitation, hypertensive crisis and hyperpyrexia (due to chlorpheniramine maleate). Simultaneous reception with antidepressants, antiparkinsonian preparations, neuroleptics can give an atropine-like effect (manifested by dry mouth, urinary retention, constipation).

The risk of developing glaucoma increases when Rinza® is taken together with GCS. Paracetamol, which is part of the preparation, reduces the effectiveness of diuretics, and also increases the risk of hepatotoxic reactions when taken together with barbiturates, diphenin, carbamazepine, rifampicin and other inducers of microsomal liver enzymes. Anticonvulsants (phenytoin, carbamazepine), which also stimulate liver microsomal enzymes, and isoniazid can increase the hepatotoxicity of paracetamol. Barbiturates reduce the antipyretic effect of paracetamol. The rate of absorption of paracetamol may increase with simultaneous use with metoclopramide and domperidone and decrease with simultaneous use with cholestyramine. The effect of paracetamol is enhanced when combined with codeine, ascorbic acid, scopolamine, chlorphenamine, propyphenazone and caffeine. The simultaneous use of paracetamol with azidothymidine can lead to the development of neutropenia. The anticoagulant effect of warfarin and other coumarins is enhanced by long-term regular intake of paracetamol. The risk of bleeding increases. Periodic reception does not matter. The parallel use of paracetamol with NSAIDs increases the risk of kidney complications. With the simultaneous use of paracetamol with hepatotoxic agents, the toxic effect of preparations on the liver increases. One of the active components of the preparation - phenylephrine hydrochloride - has an adrenomimetic effect when used with tricyclic antidepressants; simultaneous use with halothane increases the risk of ventricular arrhythmias. Rinza® reduces the hypotensive effect of guanethidine, which, in turn, enhances the α-adrenostimulating effect of phenylephrine hydrochloride. The interaction of phenylephrine hydrochloride with digoxin and cardiac glycosides leads to arrhythmias and heart attack. Phenylephrine with other sympathomimetics increases the risk of adverse cardiovascular reactions, may reduce the effectiveness of β-adrenergic receptor blockers and other antihypertensive preparations (reserpine, methyldopa) with an increased risk of hypertension and adverse cardiovascular reactions. Simultaneous use with hypnotics, barbiturates, sedatives, neuroleptics, tranquilizers, anesthetics, narcotic analgesics, alcohol can significantly increase the inhibitory effect of chlorphenamine maleate. Phenylephrine can also cause adverse reactions when combined with indomethacin and bromocriptine (severe hypertension). Rauwolfia alkaloids reduce the therapeutic effect of phenylephrine. Chlorpheniramine enhances the anticholinergic effect of atropine, antispasmodics, tricyclic antidepressants, MAO inhibitors, antiparkinsonian preparations. Caffeine increases the effect (improves bioavailability) of analgesics-antipyretics, potentiates the effects of xanthine derivatives, α- and β-adrenergic agonists, psychostimulants. Cimetidine, hormonal contraceptives, isoniazid enhance the effects of caffeine. Caffeine reduces the effect of opioid analgesics, anxiolytics, hypnotics and sedatives, is an antagonist of preparations for anesthesia and other preparations that depress the central nervous system, a competitive antagonist of preparations adenosine, ATP. With the simultaneous use of caffeine with ergotamine, the absorption of ergotamine in the gastrointestinal tract improves, with thyroid-stimulating agents - the thyroid effect increases. Caffeine lowers the concentration of lithium in the blood.

Overdose

Symptoms of a paracetamol overdose. it is known that toxic effects in adults are possible after taking 10-15 g of paracetamol. at the same time, the following symptoms may appear: pallor of the skin, anorexia, nausea, vomiting, diarrhea, a feeling of discomfort in the epigastric region (0-24 hours), gastrointestinal bleeding, increased activity of hepatic transaminases, LDH, bilirubin levels, and a decrease in the level prothrombin (24-48 hours); hepatotoxic effect, which is characterized by general (pain, weakness, weakness, increased sweating) and specific (hepatomegaly, jaundice, increased activity of liver enzymes) symptoms. hepatotoxic effect can lead to the development of hepatonecrosis and be complicated by the development of hepatic encephalopathy (thinking disorders, suppression of higher nervous activity, agitation and stupor), dvs-syndrome, hypoglycemia, metabolic acidosis, arrhythmia, convulsions, respiratory depression, coma, cerebral edema, hypocoagulation collapse. occasionally, liver dysfunction develops with lightning speed and can be complicated by renal failure. when taking high doses, disorientation, agitation, dizziness, disturbed sleep, heart rhythm, pancreatitis, bacterial infection, fungal infection, sepsis, coagulopathy, hypophosphatemia, lactic acidosis, cardiomyopathy, hypotension, respiratory failure may be noted. disorders of glucose metabolism may occur. with prolonged use of high doses, aplastic anemia, pancytopenia, agranulocytosis, neutropenia, leukopenia, thrombocytopenia are possible.

Overdose symptoms associated with the potentiation of the parasympatholytic action of the antihistamine component and the sympathomimetic action of phenylephrine. Drowsiness, after which excitement is possible (especially in children), visual disturbances, nausea, vomiting, headache, circulatory disorders, coma, convulsions, change in behavior; AG; bradycardia; atropine-like psychosis.

Symptoms of a phenylephrine hydrochloride overdose: dizziness, impaired consciousness, arrhythmias, tachycardia; tremor, hyperreflexia, irritability, anxiety.

Symptoms of chlorphenamine maleate overdose: atropine-like symptoms may be observed: mydriasis, photophobia, dryness and redness of the skin and mucous membranes, fever, intestinal atony, depression of consciousness, fever, urinary retention, tachycardia, hypertension, nausea, vomiting, agitated confusion, hallucinations, mental disorders, seizure or arrhythmia. Inhibition of the central nervous system is accompanied by respiratory disorders and disorders of the cardiovascular system (decrease in pulse rate, decrease in blood pressure up to vascular insufficiency). Rhabdomyolysis and renal failure rarely occur in patients with prolonged agitation, seizures, or in patients in a coma.

Symptoms of a caffeine overdose. Headache, tremors, hyperexcitability and irritability, heartbeat, loss of appetite, weakness, fever, hallucinations, hypokalemia, hyponatremia, increased blood glucose, metabolic acidosis, acute skeletal muscle necrosis. High doses of caffeine can cause epigastric pain, vomiting, diuresis, rapid breathing, tachycardia or cardiac arrhythmias, effects on the central nervous system (dizziness, insomnia, heat, anxiety, tremors, convulsions).

Treatment: activated charcoal, gastric lavage, symptomatic therapy, the appointment of methionine 8-9 hours after the overdose and N-acetylcysteine ​​- 12 hours later (as antidotes to paracetamol), monitoring the state of the respiratory and circulatory systems (adrenaline is contraindicated). If seizures occur, diazepam is prescribed.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C, out of the reach of children.